 Tiziana Life Sciences PLC NASDAQ:TLSA, LON:TILS is taking its nasally-administered monoclonal antibody mAB into phase II clinical trials in people with moderate to severe COVID-19. This follows an earlier study in Brazil, which showed evidence that Foralumab reduced pulmonary and systemic inflammation and was well tolerated. 